Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
timolol + latanoprost
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Timolol + latanoprost is a fixed-dose combination ophthalmic therapy used to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The combination consists of timolol, a non-selective beta-adrenergic receptor antagonist, and latanoprost, a prostaglandin F2-alpha analogue. Timolol lowers IOP by reducing the production of aqueous humor in the ciliary epithelium, while latanoprost lowers IOP by increasing the uveoscleral outflow of aqueous humor. This specific entry highlights a Phase 4 clinical research study (NCT01677507) conducted by the University of Michigan, in collaboration with the Mayo Clinic and the University of Nebraska Medical Center, which investigated the physiological factors and biomarkers that determine individual variance in IOP response to these medications in healthy volunteers.
- Brand names
- XalacomTaptiqom
- Other names
- timolol maleate + latanoprostlatanoprost + timolol maleate ophthalmic solution
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)ADRB2 (β2)ADRB1 (β1)
Beyond the preview
Go deeper on timolol + latanoprost.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on timolol + latanoprost.